{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/head-lice/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"bd894c6f-7151-57ad-ba6b-bc7270808fea","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field c7ebc398-cb96-40e8-ba91-b27c464881c4 --><h2>Changes</h2><!-- end field c7ebc398-cb96-40e8-ba91-b27c464881c4 -->","summary":null,"htmlStringContent":"<!-- begin item 06e43dcb-d66e-48d5-ada6-360aaaf833a8 --><!-- begin field e4437bc7-c281-48dc-adc7-db29827b4bf7 --><p><strong>December 2016 </strong>—<strong> </strong>reviewed. A literature search was conducted in November 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.</p><!-- end field e4437bc7-c281-48dc-adc7-db29827b4bf7 --><!-- end item 06e43dcb-d66e-48d5-ada6-360aaaf833a8 -->","topic":{"id":"ca628e0c-ce13-5d42-b253-54a69b51d894","topicId":"e347bf30-a684-4ab6-843a-e2d2929ff4ca","topicName":"Head lice","slug":"head-lice","lastRevised":"Last revised in December 2016","chapters":[{"id":"c07f1a11-a6fc-5dc9-b489-c79c00eed1b2","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1c07399f-6032-532b-aab2-6e7a99c32991","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"352c1214-5167-5f31-b6e9-2cf3e28637d9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"bd894c6f-7151-57ad-ba6b-bc7270808fea","slug":"changes","fullItemName":"Changes"},{"id":"a3f89268-7fb7-52ef-a4c5-421d1d3e4419","slug":"update","fullItemName":"Update"}]},{"id":"6c7acc5e-bafe-57e2-9ff5-75693571b01f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d2aaf293-6ebf-5a60-b90f-9a548a5a36ff","slug":"goals","fullItemName":"Goals"},{"id":"8234f1df-9ff1-51f0-ada4-683b91f6f2cc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b824d73b-ebfe-5acc-a3d6-000ef3a3e102","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5b4135ed-764c-5eb2-a4b8-d7ecee5b4535","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cf25fdab-c543-50d9-83c6-37882f9cfc6c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"df0e67e2-a8c4-53b1-98a4-02c672e57215","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"14783c10-a368-59fe-b2b6-ea9fe2d8669f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e05fe98-3313-5584-8979-95ac9bf967bb","slug":"definition","fullItemName":"Definition"},{"id":"bd55008c-d8e0-5450-828d-0ca6101dc5b6","slug":"life-cycle-of-head-lice","fullItemName":"Life cycle of head lice"},{"id":"04a195de-19ca-5752-9d1e-89f9de23b0e8","slug":"transmission-of-head-lice","fullItemName":"Transmission of head lice"},{"id":"e21d9025-2ac4-59c8-a69f-297f822ddce3","slug":"prevalence-risk-factors","fullItemName":"Prevalence and risk factors"},{"id":"d5fbf6f2-f317-52e9-a482-69a7794229f1","slug":"prognosis","fullItemName":"Prognosis"},{"id":"71077b2e-cace-5a02-a4e5-3e0c24c81753","slug":"complications","fullItemName":"Complications"}]},{"id":"f194f6ee-3f32-5b37-a86c-9e7e02587010","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0e7d106a-6cfc-5453-8aa6-e1feb7b8d488","slug":"confirming-active-infestation","fullItemName":"Confirming active infestation"},{"id":"5418af94-f803-571e-87f9-eb808e4cd113","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3b0c16d9-b6dd-563a-9a9c-da334c6934e7","fullItemName":"Management","slug":"management","subChapters":[{"id":"78872245-0ffd-5376-93db-f8711b8998bf","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2b2e5f71-f069-529e-b3ca-a5afb883c050","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"80f3e570-b1ec-55f0-9658-edee2b410968","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b892f92e-2a19-5bc1-b1e6-fda30e98a065","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2a7b697d-4010-539b-bf3f-6083d0f1ffd9","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"499f4fb3-f508-5bae-b497-9e1f2061b736","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"95a4f7cf-4c43-5132-914f-8d5e2a5315c9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3ff61270-dae1-5f42-977f-4be4c04c3af8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"00aef18b-03ff-571a-bf3b-b767d38c3304","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"352c1214-5167-5f31-b6e9-2cf3e28637d9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"04db1db9-c074-5d82-8d52-07324e29cb36","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 4e9e0857-05ec-4e03-a35a-2eed9343f112 --><h3>Previous changes</h3><!-- end field 4e9e0857-05ec-4e03-a35a-2eed9343f112 -->","summary":null,"htmlStringContent":"<!-- begin item 3fccb37a-a2ec-4989-93bb-2c8f8ef94fca --><!-- begin field d64885c9-79f5-4937-852a-503c8b53f578 --><p><strong>September 2015 </strong>—<strong> </strong>reviewed. A literature search was conducted in August 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made; however, the topic has undergone minor restructuring.</p><p><strong>February 2015 </strong>— minor update. Hair loss has been reported as a very rare adverse effect of Hedrin<sup>®</sup> (dimeticone 4%).</p><p><strong>March 2014 </strong>— minor update. Minor rewording of several sections to clarify the difference between nits (empty shells of hatched eggs) and live louse eggs. Additional information nodes in Background Information have been changed to main nodes to improve the flow of the topic.</p><p><strong>May 2013 </strong>— minor update. The text regarding Lyclear SprayAway<sup>®</sup> has been changed or deleted as this product has been discontinued. The prescription for this product has also been removed.</p><p><strong>January 2013 </strong>— minor update. Reference to a published paper inserted regarding the mode of action of Full Marks Solution<sup>®</sup>. This replaces a personal communication reference.</p><p><strong>March 2011 </strong>— minor update. NYDA<sup>®</sup> (dimeticone 92% is now prescribable on the NHS). Issued in June 2011.</p><p><strong>February 2011 </strong>— minor update. Advice from the manufacturer that isopropyl myristate and cyclomethicone solution (Full Marks Solution<sup>®</sup>) works by removing the wax coating on the louse exoskeleton, leading to uncontrollable dehydration and subsequent death has been added to the topic . Issued in February 2011.</p><p><strong>December 2010 </strong>— minor update. Further detail added to the Basis for recommendation section of the Treatment recommendations to clarify why Hedrin<sup>®</sup> lotion is the only formulation of Hedrin<sup>®</sup> offered in this CKS topic. Issued in December 2010.</p><p><strong>April 2010 </strong>— minor update. Minor rewording of several sections. Issued in April 2010.</p><p><strong>November 2009 to March 2010 </strong>— topic revised. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence. Changes to recommendations include:</p><ul><li>Isopropryl myristate and cyclomethicone (Full Marks Solution<sup>®</sup>) and coconut, anise, and ylang ylang spray (Lyclear SprayAway<sup>®</sup>) are now recommended as treatment options.</li><li>Phenothrin and carbaryl are no longer recommended because they are no longer marketed in the UK.</li></ul><p><strong>December 2008</strong> — minor update. The topic now includes the advice that people using dimeticone (Hedrin<sup>®</sup>) should avoid naked flames, cigarettes, and other sources of ignition while treatment is underway updated following a Medicines & Healthcare products Regulatory Agency (MHRA) Drug Safety Update. Issued in January 2009.</p><p><strong>November 2007 </strong>—<strong> </strong>minor update to text. Malathion is now licensed for a second application after 7 days. The recommendation for a second application of insecticide 7 days after the first is unlicensed for phenothrin, permethrin, and carbaryl, and is different to the information supplied by the manufacturers: their package inserts state that a single application is sufficient. Issued in December 2007.</p><p><strong>July 2007</strong> — minor update to text of instructions for wet combing for the treatment of head lice. Issued in August 2007.</p><p><strong>January to April 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>August 2003</strong><strong> </strong>— reviewed. Validated in December 2003 and issued in February 2004.</p><p><strong>November 2000</strong> — rewritten. Validated in March 2001 and issued in June 2001.</p><!-- end field d64885c9-79f5-4937-852a-503c8b53f578 --><!-- end item 3fccb37a-a2ec-4989-93bb-2c8f8ef94fca -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}